No Single Market, no single prices
This article was originally published in Scrip
The European Commission is planning to review the “Transparency Directive” on pricing and reimbursement. And so it seems somewhat ironic that the response from the European Industry Body, EFPIA, has been to say that nothing in the directive must compromise the “confidentiality” of pricing arrangements between companies and payers. Is EFPIA forging new ground in double-speak by asking for secrecy to be written into policies on openness?
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.